Mandy Jackson

San Diego

Managing Editor, US Commercial News at Scrip

Managing Editor, US Commercial News at The Pink Sheet

I am Managing Editor, US Commercial News, for the Citeline Commercial publications Scrip and The Pink Sheet. Views expressed here are strictly my own.

Featured in: Favicon

informa.com (+4) Favicon

pharmamedtechbi.com Favicon

clinicalleader.com Favicon

citeline.com Favicon

xconomy.com Favicon

invivo.citeline.com

Articles

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

1 week ago | insights.citeline.com | Mandy Jackson

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind DownSoleus Capital, BML Capital Management Seek Firms’ CashRestructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.
Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

1 week ago | insights.citeline.com | Mandy Jackson

Trump Executive Order On Drug Pricing Is A Mixed Bag For PharmaFast Followers May Win Quicker Path To ApprovalThe order aims to eliminate the gap between small molecules and biologics in terms of the time to IRA-mandated Medicare negotiations, but pharma’s gain could be offset by other directives. Small molecule developers could benefit from Trump's executive order but specifics are unclear (Shutterstock)
Finance Watch: Biopharma Sees An Early April VC Mega-Round Surge

1 week ago | insights.citeline.com | Mandy Jackson

Finance Watch: Biopharma Sees An Early April VC Mega-Round SurgeMerida, RayThera, Neurona, Glycomine Join Atsena, AIRNAPrivate Company Edition: After Q1 venture capital investment slumped relative to 2024 totals due to declines in both smaller financings and mega-rounds, Q2 started off with six $100m-plus financings in the first half of April after there were only three in February and six in all off March.
Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

1 week ago | insights.citeline.com | Mandy Jackson

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series CDrug Developer Focused On Glycosylation DisordersLead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study. Glycomine raises $115m in venture capital funding (Shutterstock)
Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

2 weeks ago | insights.citeline.com | Mandy Jackson

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds DipLast-Minute $600m Push Didn’t Save QuarterEvaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters. First quarter 2025 VC financings fell short of most 2024 venture funding levels (Shutterstock)
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise

3 weeks ago | insights.citeline.com | Mandy Jackson

Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives RiseSandoz Accesses $2bn Credit Facility, Issues $1bn In BondsPublic Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
Amgen’s Rare Disease Portfolio Grows With Second Approved Uplizna Indication

3 weeks ago | insights.citeline.com | Mandy Jackson

Amgen’s Rare Disease Portfolio Grows With Second Approved Uplizna IndicationGeneralized Myasthenia Gravis Could Be ThirdThe US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication. Uplizna's approval in IgG4-RD adds to the rare disease foundation Amgen built with its Horizon acquisition (Shutterstock)
AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

3 weeks ago | insights.citeline.com | Mandy Jackson

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round Previously Raised $90m In Series A CashCEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
Peter Marks’ Departure From FDA Rattles Biopharma Industry

3 weeks ago | insights.citeline.com | Mandy Jackson

Peter Marks’ Departure From FDA Rattles Biopharma IndustryXBI Reaches A New 2025 LowStock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns. FDA review of vaccines and cell and gene therapies could be held up under new CBER leadership (Shutterstock)
DRI Capital raises $1.45bn for royalty deals

3 weeks ago | insights.citeline.com | Mandy Jackson

DRI Capital raises $1.45bn for royalty dealsDRI Capital has raised $1.45bn in private equity for a fund called Drug Royalty III, which gives the Canadian firm $3bn in drug royalty buying capacity when its new cash is combined with available debt.